Abiomed, Inc.
ABMD · NASDAQ
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $266 | $277 | $270 | $261 |
| % Growth | -4.1% | 2.7% | 3.3% | – |
| Cost of Goods Sold | $49 | $53 | $51 | $48 |
| Gross Profit | $217 | $225 | $218 | $214 |
| % Margin | 81.6% | 81% | 80.9% | 81.8% |
| R&D Expenses | $42 | $40 | $44 | $41 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $117 | $118 | $110 | $108 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $159 | $158 | $153 | $148 |
| Operating Income | $58 | $66 | $65 | $65 |
| % Margin | 21.8% | 23.8% | 24.1% | 24.7% |
| Other Income/Exp. Net | $81 | $4 | $10 | -$7 |
| Pre-Tax Income | $139 | $70 | $75 | $58 |
| Tax Expense | $33 | $15 | $14 | $12 |
| Net Income | $106 | $55 | $60 | $46 |
| % Margin | 39.9% | 19.7% | 22.4% | 17.5% |
| EPS | 2.34 | 1.2 | 1.33 | 1.01 |
| % Growth | 95% | -9.8% | 31.7% | – |
| EPS Diluted | 2.32 | 1.19 | 1.31 | 1 |
| Weighted Avg Shares Out | 45 | 46 | 46 | 46 |
| Weighted Avg Shares Out Dil | 46 | 46 | 46 | 46 |
| Supplemental Information | – | – | – | – |
| Interest Income | $81 | $4 | $10 | $0 |
| Interest Expense | $81 | $4 | $10 | $0 |
| Depreciation & Amortization | $7 | $7 | $7 | $7 |
| EBITDA | $226 | $80 | $92 | $72 |
| % Margin | 85% | 28.9% | 34% | 27.4% |